Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
暂无分享,去创建一个
A. Eskander | N. L. Look Hong | T. Hanna | S. Seung | P. Nguyen | S. Bateni | Nicole Mittmann | Matthew Jalink | Arjun Gupta | Kelvin K W Chan
[1] C. Earle,et al. Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization , 2023, Cancer medicine.
[2] Kathleen F. Kerr,et al. Diagnostic error, uncertainty, and overdiagnosis in melanoma. , 2022, Pathology.
[3] E. Eisenhauer,et al. The Time Toxicity of Cancer Treatment. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Hellmann,et al. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Arjun Gupta,et al. Caregiver Burden #419. , 2021, Journal of palliative medicine.
[6] S. Swetter,et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[8] P. Gibbs,et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.
[9] E. Itakura,et al. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan , 2020, Journal of medical economics.
[10] G. Hospers,et al. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs , 2020, Cancers.
[11] V. Sondak,et al. Systemic Therapy for Melanoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Brenner,et al. Projected estimates of cancer in Canada in 2020 , 2020, Canadian Medical Association Journal.
[13] C. Schmults,et al. Cost and Utilization of Immunotherapy and Targeted Therapy for Melanoma: Cross-Sectional Analysis in the Medicare Population, 2013 and 2015. , 2020, Journal of the American Academy of Dermatology.
[14] G. Fletcher,et al. Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline. , 2020, Current oncology.
[15] M. Barry,et al. Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] C. Earle,et al. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. , 2020, CMAJ open.
[17] C. Earle,et al. The generation of two specific cancer costing algorithms using Ontario administrative databases. , 2019, Current oncology.
[18] G. Hortobagyi,et al. Current Landscape of Immunotherapy in Breast Cancer: A Review. , 2019, JAMA oncology.
[19] P. Ascierto,et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Joe Y. Chang,et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors , 2018, Journal of Immunotherapy for Cancer.
[21] E. Eisenhauer,et al. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).
[22] Q. Miao,et al. Disparities in diagnosis of advanced melanoma: a population-based cohort study. , 2018, CMAJ open.
[23] Zhiyi Li,et al. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly. , 2018, American health & drug benefits.
[24] J. Mauskopf,et al. Direct costs associated with adverse events of systemic therapies for advanced melanoma , 2018, Medicine.
[25] D. Schadendorf,et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.
[26] Kelvin K. W. Chan,et al. The economic burden of cancer care in Canada: a population-based cost study. , 2018, CMAJ open.
[27] A. Ribas,et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.
[28] P. Ascierto,et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.
[29] A. Hauschild,et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.
[30] Brian J Moore,et al. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data: The AHRQ Elixhauser Comorbidity Index , 2017, Medical care.
[31] A. Gesierich,et al. Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.
[32] C. Rubio-Terrés,et al. Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review , 2017, PharmacoEconomics.
[33] M. Weichenthal,et al. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study) , 2017, The oncologist.
[34] A. Hauschild,et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.
[35] C. Berking,et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.
[36] M. Amonkar,et al. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries , 2016, Journal of medical economics.
[37] B. Barber,et al. Economic burden of toxicities associated with treating metastatic melanoma in eight countries , 2015, The European Journal of Health Economics.
[38] V. Schabert,et al. Comparative healthcare costs in patients with metastatic melanoma in the USA , 2015, Melanoma research.
[39] J. Emery,et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review , 2015, British Journal of Cancer.
[40] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[41] Eric J Feuer,et al. Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.
[42] M. Porter,et al. What is value in health care? , 2010, The New England journal of medicine.
[43] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[44] P. Austin,et al. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.
[45] I. Abraham,et al. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma , 2019, JAMA dermatology.
[46] A. Khorana,et al. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database , 2018, Journal of the American Academy of Dermatology.